Roche Holding AG (OTC:RHHBY) reportedly turned down a potential blockbuster weight-loss pill in 2018, allowing Eli Lilly And Co (NYSE:LLY) to acquire the drug, now known as orforglipron ...

In an interview with pharmaphorum, Marius Scholtz, country medical lead for Roche UK, said the drug will have around the same yearly cost in relapsing disease as Novartis’ once-daily pill ...

Against all the odds, Roche's Genentech unit has won FDA approval for its clot-busting drug TNKase as a treatment for acute ischaemic stroke, after all but abandoning the project a couple of years ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics ( VKTX 2.08 ...

In 2016, Ionis won approval for an infusion called Spinraza. After Zolgensma was approved, Roche won approval for a pill. Last year, Scholar Rock announced data for an antibody that targets ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Roche has signed the biggest-ever obesity drug deal with a $5.3bn licensing agreement for a next-generation ...